Since previous studies have shown that selectively inhibiting BACE-1 processing of APP and increasing non-amyloidogenic processing of APP by promoting α-secretase cleavage might have therapeutic importance for AD [63, 64], Sierks and collaborators generated a bispecific recombinant antibody fragment, diabody, combining a scFV, named iBsec1 and binding to BACE-1, and another scFv, named Asec1a that has been shown to promote non-amyloidogenic processing of APP [65]. This evidence concerns the gene APP and Alzheimer disease.